Fund managers including Milford Asset Management, Monash Investors, Equity Trustees Asset Management, Yarra Capital Management, Pengana Capital Group, Mint Asset Management, Selector Funds Management, Clime Investment Management, Glennon Small Companies, Bennelong Australian Equity Partners, Sage Capital, SG Hiscock & Company, Antares Capital, Perennial Partners, Sterling Managed Investments, Eiger Capital, Australian Eagle Asset Management, Pendal Group, Greencape Capital, Ellerston Capital, Lennox Capital Partners and Ralton Asset Management have invested in Telix Pharmaceuticals Ltd (ASX:TLX).

Managers highlight strong revenue growth in precision medicine imaging, trading ahead of guidance, a partnership with United Imaging Healthcare and progress in late-stage trials, according to Selector, Equity Trustees and Antares.

Perennial notes Telix fell 14% in a month despite positive results, showing volatility tied to biotech sector sentiment, and the company's longer-term value depends on regulatory and clinical success for its therapy pipeline.

Telix Pharmaceuticals Limited is a Melbourne-based biopharmaceutical company focused on the development and commercialization of clinical-stage radiopharmaceutical oncology assets. Founded in 2015, the company operates across three segments: Commercial, Product Development, and Group and Unallocated. Its primary commercial asset is Illuccix. The pipeline targets prostate, renal, and glioblastoma cancers, with key products including TLX250, TLX591, and TLX101. Telix specializes in advanced cancer care solutions, driving innovation in molecularly-targeted radiation through its global product development and regulatory efforts.